The management of patients with patent foramen ovale and stroke
The management of patients with patent foramen ovale (PFO) and stroke remains uncertain. What is known is that PFO is a very common finding in the general population. The risk of initial and recurrent stroke in individuals with PFO is relatively low. With the advent of transesophageal echocardiography, PFO is more commonly being diagnosed. There are insufficient data to support a benefit of warfarin over aspirin in preventing recurrent stroke in most patients with PFO. In those with PFO and a history of a procoagulant state or deep venous thrombosis, anticoagulation may be indicated after weighing the risks of anticoagulation against potential benefits in preventing recurrent stroke. PFO closure does not guarantee the prevention of future stroke and should be addressed case by case, with consideration of patients for entry into ongoing clinical trials of safety, efficacy, and durability.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 1.Heart Disease and Stroke Statistics-2005 Update. Dallas, TX: American Heart Association; 2005.Google Scholar
- 5.Hagen PT, Scholz DG, Edwards WD: Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clinic Proc 1984, 59:17–20.Google Scholar
- 6.Meissner I, Whisnant JP, Khandheria BK, et al.: Prevalence of potential risk factors for stroke assessed by transesophageal echocardiography: the SPARC study. Stroke Prevention: Assessment of Risk in a Community. Mayo Clin Proc 1999, 74:862–869. A unique, prospective population-based, longitudinal TEE study.PubMedCrossRefGoogle Scholar
- 7.Meissner I: Outcome data from SPARC. J Am Coll Cardiol 2005, In press.Google Scholar
- 8.Agmon Y, Khandheria BK, Meissner I, et al.: Comparison of frequency of patent foramen ovale by transesophageal echocardiography in patients with cerebral ischemic events versus in subjects in the general population. Am J Cardiol 2001, 88:330–332. Population-based insights into the variability of PFO detection rates.PubMedCrossRefGoogle Scholar
- 14.Lechat P, Mas JL, Lascault G, et al.: Prevalence of patent foramen ovale in young stroke patients. Lancet 1988, 2:11–12.Google Scholar
- 22.Roijer A, Lindfren A, Algotsson L, et al.: Cardiac changes in stroke patients and controls evaluated with transesophageal echocardiography. Scand CardiovascJ 1997, 31:329–337. A population-based study showing similar PFO prevalence in patients with stroke, compared with randomly selected community controls.Google Scholar
- 25.MasJL, Arquizan C, Lamy C, et al.: Patent Foramen Ovale and Atrial Septal Aneurysm Study Group. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. NEnglJMed 2001, 345:1740–1746. A substantially sized multicenter study evaluating stroke recurrence in patients with PFO, illustrating the controversies in management.CrossRefGoogle Scholar
- 26.HommaS, Sacco RL, Di Tullio MR, et al.: PFO in Cryptogenic Stroke (PICCS) Investigators. Effect of medical treatment in stroke patients with patent foramen ovale: Patent Foramen Ovale in Cryptogenic Stroke Study. Circulation 2002, 105:2625–2631. Results of a clinical trial evaluating aspirin versus warfarin in patients with PFO.PubMedCrossRefGoogle Scholar
- 27.Messe SR, Silverman IE, Kizer Jr: Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2004, 62:1042–1050. Evidence-based guidelines for management of patients with cryptogenic stroke, PFO, or ASA.PubMedGoogle Scholar